|
1.
|
de Groen PC, Gores GJ, LaRusso NF,
Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med.
341:1368–1378. 1999.
|
|
2.
|
Jung KW, Park S, Kong HJ, et al: Cancer
statistics in Korea: incidence, mortality, survival, and prevalence
in 2009. Cancer Res Treat. 44:11–24. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Miyakawa S, Ishihara S, Horiguchi A,
Takada T, Miyazaki M and Nagakawa T: Biliary tract cancer
treatment: 5,584 results from the Biliary Tract Cancer Statistics
Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg.
16:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Horgan AM, Amir E, Walter T and Knox JJ:
Adjuvant therapy in the treatment of biliary tract cancer: a
systematic review and meta-analysis. J Clin Oncol. 30:1934–1940.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Cereda S, Belli C and Reni M: Adjuvant
treatment in biliary tract cancer: to treat or not to treat? World
J Gastroenterol. 18:2591–2596. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Takada T, Amano H, Yasuda H, et al: Is
postoperative adjuvant chemotherapy useful for gallbladder
carcinoma? A phase III multicenter prospective randomized
controlled trial in patients with resected pancreaticobiliary
carcinoma. Cancer. 95:1685–1695. 2002. View Article : Google Scholar
|
|
7.
|
Neoptolemos JP, Moore MJ, Cox TF, et al:
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid
or gemcitabine vs. observation on survival in patients with
resected periampullary adenocarcinoma: the ESPAC-3 periampullary
cancer randomized trial. JAMA. 308:147–156. 2012. View Article : Google Scholar
|
|
8.
|
Namwat N, Amimanan P, Loilome W, et al:
Characterization of 5-fluorouracil-resistant cholangiocarcinoma
cell lines. Chemotherapy. 54:343–351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Yamada H, Iinuma H and Watanabe T:
Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes’
stage B and C colorectal cancer patients treated with oral
5-fluorouracil-based adjuvant chemotherapy. Oncol Rep. 19:729–735.
2008.PubMed/NCBI
|
|
10.
|
Soong R, Shah N, Salto-Tellez M, et al:
Prognostic significance of thymidylate synthase, dihydropyrimidine
dehydrogenase and thymidine phosphorylase protein expression in
colorectal cancer patients treated with or without
5-fluorouracil-based chemotherapy. Ann Oncol. 19:915–919. 2008.
View Article : Google Scholar
|
|
11.
|
Longley DB, Harkin DP and Johnston PG:
5-Fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Marsh S and McLeod HL: Cancer
pharmacogenetics. Br J Cancer. 90:8–11. 2004. View Article : Google Scholar
|
|
13.
|
Popat S, Matakidou A and Houlston RS:
Thymidylate synthase expression and prognosis in colorectal cancer:
a systematic review and meta-analysis. J Clin Oncol. 22:529–536.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kim JS, Kim MA, Kim TM, et al: Biomarker
analysis in stage III–IV (M0) gastric cancer patients who received
curative surgery followed by adjuvant 5-fluorouracil and cisplatin
chemotherapy: epidermal growth factor receptor (EGFR) associated
with favourable survival. Br J Cancer. 100:732–738. 2009.
|
|
15.
|
Kwon HC, Roh MS, Oh SY, et al: Prognostic
value of expression of ERCC1, thymidylate synthase, and glutathione
S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in
advanced gastric cancer. Ann Oncol. 18:504–509. 2007. View Article : Google Scholar
|
|
16.
|
Takebe N, Xu LC, MacKenzie KL, Bertino JR
and Moore MA: Methotrexate selection of long-term culture
initiating cells following transduction of CD34+ cells
with a retrovirus containing a mutated human dihydrofolate
reductase gene. Cancer Gene Ther. 9:308–320. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Salonga D, Danenberg KD, Johnson M, et al:
Colorectal tumors responding to 5-fluorouracil have low gene
expression levels of dihydropyrimidine dehydrogenase, thymidylate
synthase, and thymidine phosphorylase. Clin Cancer Res.
6:1322–1327. 2000.
|
|
18.
|
Hasegawa S, Seike K, Koda K, et al:
Thymidine phosphorylase expression and efficacy of adjuvant
doxifluridine in advanced colorectal cancer patients. Oncol Rep.
13:621–626. 2005.PubMed/NCBI
|
|
19.
|
Brown NS and Bicknell R: Thymidine
phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J. 334(Pt
1): 1–8. 1998.PubMed/NCBI
|
|
20.
|
Takebayashi Y, Akiyama S, Akiba S, et al:
Clinicopathologic and prognostic significance of an angiogenic
factor, thymidine phosphorylase, in human colorectal carcinoma. J
Natl Cancer Inst. 88:1110–1117. 1996. View Article : Google Scholar
|
|
21.
|
Diasio RB and Harris BE: Clinical
pharmacology of 5-fluorouracil. Clin Pharmacokinet. 16:215–237.
1989. View Article : Google Scholar
|
|
22.
|
Johnston PG, Drake JC, Trepel J and
Allegra CJ: Immunological quantitation of thymidylate synthase
using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive
and -resistant human cancer cell lines. Cancer Res. 52:4306–4312.
1992.
|
|
23.
|
Edler D, Kressner U, Ragnhammar P, et al:
Immunohistochemically detected thymidylate synthase in colorectal
cancer: an independent prognostic factor of survival. Clin Cancer
Res. 6:488–492. 2000.PubMed/NCBI
|
|
24.
|
Lenz HJ, Hayashi K, Salonga D, et al: p53
point mutations and thymidylate synthase messenger RNA levels in
disseminated colorectal cancer: an analysis of response and
survival. Clin Cancer Res. 4:1243–1250. 1998.PubMed/NCBI
|
|
25.
|
Soong R and Diasio RB: Advances and
challenges in fluoropyrimidine pharmacogenomics and
pharmacogenetics. Pharmacogenomics. 6:835–847. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Moghaddam A, Zhang HT, Fan TP, et al:
Thymidine phosphorylase is angiogenic and promotes tumor growth.
Proc Natl Acad Sci USA. 92:998–1002. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
O’Brien TS, Fox SB, Dickinson AJ, et al:
Expression of the angiogenic factor thymidine
phosphorylase/platelet-derived endothelial cell growth factor in
primary bladder cancers. Cancer Res. 56:4799–4804. 1996.PubMed/NCBI
|
